Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Background—Both clopidogrel and prasugrel require biotransformation to active metabolites
by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of …

Background Clopidogrel requires transformation into an active metabolite by cytochrome P-
450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are …

Clopidogrel, a prodrug, must be activated by hepatic cytochrome P450 (CYP) isoenzymes
before being able to irreversibly block the platelet adenosine 5′-diphosphate (ADP) …

Background: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A
(CYP3A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether …

Clopidogrel is a thienopyridine derivative with ADP-antagonistic activity and is widely used
for the prevention of ischemic events in patients who have suffered a stroke, non-ST …

The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …

Aims The metabolic pathways leading to the formation of prasugrel and clopidogrel active
metabolites differ. We hypothesized that decreased CYP2C19 activity affects the …